Imatinib tackles lymphomavia the PDGFRβ+ pericyte

Blood

Volumn 121, Issue 26, 2013, Pages 5107-5108

  Chute, John P ^a   Himburg, Heather A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; BENZAMIDE DERIVATIVE; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER PROGNOSIS; CANCER REGRESSION; CLINICAL TRIAL (TOPIC); ENDOTHELIUM CELL; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MICROVASCULATURE; NONHUMAN; PATHOGENESIS; PERICYTE; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; ANIMAL; DRUG EFFECT; NEOVASCULARIZATION (PATHOLOGY); NOTE; T CELL LYMPHOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BENZAMIDES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PIPERAZINES; PYRIMIDINES;

EID: 84884171117     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-501205     Document Type: Review

References (7)

1. Ruan J, Luo M, Wang C, et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 2013;121(26):5192-5202.
2. Hamada J, Cavanaugh PG, Lotan O, Nicolson GL. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer. 1992; 66(2):349-354.
3. Lenz G, Wright G, Dave SS, et al; Lymphoma/ Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-2323.
4. Stopeck AT, Unger JM, Rimsza LM, et al. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood. 2012;120(6):1210-1217.
5. Stopeck AT, Unger JM, Rimsza LM, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma. 2009; 50(5):728-735.
6. Shih SC, Ju M, Liu N, Mo JR, Ney JJ, Smith LE. Transforming growth factor beta1 induction of vascular endothelial growth factor receptor 1: mechanism of pericyte-induced vascular survival in vivo. Proc Natl Acad Sci USA. 2003;100(26):15859-15864. (Pubitemid 38021080)
7. Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci. 2011; 14(11):1398-1405.